Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

Biochemical and objective response to abiraterone acetate withdrawal: Incidence and clinical relevance of a new scenario for castration-resistant prostate cancer

By O. Caffo, A. Palermo, A. Veccia, F. Maines, F. Chierichetti, A. Berruti and E. Galligioni.Urology, Volume 82, Issue 5, November 2013, Pages 1090-1093.


External reference

Editor's comments

This, to the best of my knowledge , is the first report demonstrating an abiraterone withdrawal effect (similar to anti-androgen withdrawal). More data is required to better assess the potential of this phenomenon.



Register to be notified when new content is published. Only your name, country and email address needed.

Subscribe »

Latest webcast

ESMO 2016 Symposium webcast

Individualizing treatment in
metastatic prostate cancer: there
is no “one-size-fits-all” approach

EAU 2016 Scientific Programme and Sessions

View the Scientific Programme and Sessions of the 2016 EAU Annual Congress, Munich, Germany.

The editorial independence of the resource centre is mandatory and recognized by the EAU and Elsevier.
The journal articles, videos and statements published on the resource centre have been selected independently and without influence from Elsevier, European Urology Editors or the sponsor and do not necessarily reflect their opinions or views

Search this site

Search form